ClinicalTrials.Veeva

Menu
New Horizon Research Center | Miami, FL logo

New Horizon Research Center | Miami, FL

Research site

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Metformin
LY3556050
Maridebart Cafraglutide
LY3857210
LY3526318
LY3841136
Upadacitinib
LY3009104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Steven Hernandez

Verified by this site

Active trials

27 of 122 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The main purpose of this study is to test the safety and efficacy of study drug for the treatment of chronic low back pain (CLBP). This trial is part...

Begins enrollment this month
Chronic Pain
Low Back Pain
Drug: Placebo
Drug: LY4065967

The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP)...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: Placebo
Drug: LY4065967

The main purpose of this study is to test the safety and efficacy of study drug for the treatment of knee pain due to osteoarthritis (OA). This trial...

Begins enrollment this month
Chronic Pain
Osteoarthritis, Knee
Drug: LY4065967
Drug: Placebo

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3016859 ISA
Drug: Placebo Oral

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3532226
Drug: LY3841136

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the...

Begins enrollment in 2 months
Diabetes Mellitus, Type 2
Drug: Placebo CagriSema
Drug: CagriSema

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo....

Active, not recruiting
Diabetes Mellitus, Type 2
Diabetic Peripheral Neuropathy
Drug: CagriSema (Cagrilintide B and Semaglutide I)
Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight....

Enrolling
Obesity
Type 2 Diabetes
Drug: Cagrisema
Drug: Semaglutide

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Cagrilintide
Drug: Semaglutide

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants...

Enrolling
Overweight
Obesity
Drug: Eloralintide
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Active, not recruiting
Type 2 Diabetes Mellitus (T2DM)
Drug: Maridebart Cafraglutide
Drug: Placebo

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weig...

Enrolling
Overweight and/or Obesity
Nutrition Disorders
Drug: PF-08653944
Drug: PF-08653945

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 d...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and sa...

Not yet enrolling
Overweight
Obesity
Drug: Macupatide
Drug: Eloralintide

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a...

Active, not recruiting
COVID-19
SARS-COV-2 Infection
Biological: Placebo
Biological: BNT162b2 Vaccine

Trial sponsors

Lilly logo
Pfizer logo
Novo Nordisk logo
Boehringer Ingelheim logo
AbbVie logo
Amgen logo
C
G
G
Ironwood Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems